Rotenone Exposed Dopaminergic Neurons is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Rotenone is a mitochondrial complex I inhibitor that selectively induces dopaminergic neuron degeneration, making it a crucial tool for modeling Parkinson's disease in vitro and in vivo.
This page provides comprehensive information about the subject's role in neurodegenerative diseases. The subject participates in various molecular pathways and cellular processes relevant to Alzheimer's disease, Parkinson's disease, and related conditions.
- Direct binding to mitochondrial complex I
- Blocks NADH dehydrogenase activity
- Reduces electron transport
- Decreases ATP production
- Increased superoxide production
- Mitochondrial ROS generation
- Lipid peroxidation
- Protein oxidation
- Loss of mitochondrial membrane potential
- Reduced ATP synthesis
- Impaired calcium buffering
- Swollen mitochondria
- Dopaminergic neuron death
- α-Synuclein aggregation
- Lewy body-like inclusions
- Dendritic arbor simplification
- Primary mesencephalic cultures
- Dopaminergic cell lines (N27, SH-SY5Y)
- iPSC-derived dopaminergic neurons
- Organotypic slice cultures
- Chronic rotenone infusion rats
- Rotenone-treated mice
- Drosophila rotenone models
- Reduced locomotion
- Gait abnormalities
- Tremor
- Postural instability
- Gastrointestinal dysfunction
- Sleep disturbances
- Depression-like behavior
- Cognitive deficits
- Selective dopaminergic loss
- α-Synuclein aggregation
- Mitochondrial dysfunction
- Oxidative stress
- More widespread toxicity
- Faster progression
- Different pattern of pathology
- Mitochondrial protectants
- Antioxidants
- Anti-inflammatory agents
- Anti-α-synuclein compounds
- AAV vectors
- CRISPR approaches
- Neurotrophic factors
The study of Rotenone Exposed Dopaminergic Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Betarbet et al., Chronic systemic pesticide exposure reproduces features of Parkinson's disease (2000)
- Sherer et al., Rotenone model of Parkinson's disease (2003)
- Cannon et al., Robenone-induced neurodegeneration (2009)
- Liu et al., Rotenone and α-synuclein aggregation (2019)
The rotenone model is one of the most widely used experimental models for Parkinson's disease. Rotenone is a natural pesticide found in the roots of certain plants (Derris elliptica, Lonchocarpus utilialis).
- First used in 1980s as PD model
- Produces selective dopaminergic degeneration
- Recreates key PD features: Lewy bodies, motor deficits
Rotenone directly binds to the ND1 subunit of complex I (NADH:ubiquinone oxidoreductase), blocking electron transfer from iron-sulfur clusters to ubiquinone. This leads to:
- Electron leakage and ROS generation
- ATP depletion
- Loss of mitochondrial membrane potential
- Superoxide formation: Complex I leakage
- Hydrogen peroxide: SOD conversion
- Hydroxyl radical: Fenton reaction
- Peroxynitrite: NO + superoxide
- α-Synuclein phosphorylation
- Ubiquitination defects
- Proteasome dysfunction
- Autophagy impairment
¶ Lewy Body-like Inclusions
- Phosphorylated α-synuclein
- Ubiquitin positive
- Perikaryal and neuritic distribution
- Caspase-dependent apoptosis
- Necrotic components
- Selective vulnerability of substantia nigra
- Microglial activation
- Astrogliosis
- Inflammatory cytokine release
- Cylinder test (forelimb asymmetry)
- Rotarod (motor coordination)
- Gait analysis (stride length)
- Pole test (bradykinesia)
- Olfactory testing
- Gastrointestinal transit
- Sleep analysis
- Cognitive tests
- MAO-B inhibitors
- Mitochondrial protectors
- Antioxidants
- Anti-inflammatory agents
- Parkin overexpression
- PINK1 manipulation
- DJ-1 rescue strategies
- Systemic toxicity
- Variable model quality
- Non-selective neuronal loss
- Species differences
- Betarbet et al., Chronic systemic pesticide exposure (2000)
- Sherer et al., Rotenone model of PD (2003)
- Cannon et al., Reproducible rotenone model (2009)